CGEM · Cullinan Therapeutics, Inc.
$15.71
+0.08 (+0.51%)
At close · Oct 8
Return incl. dividend (before tax)
Market Cap
$965.19M
Shares
64.35M
Volume · Oct 8
392.57K
Avg daily vol (3M)
867.31K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$15.63
Open$15.95
Day$15.47–16.46
52W close$5.89–22.95
Avg vol 30d1.1M
Short int9.6M · 15.0% float · 10.9d
Short vol48%
Last earningsSep 14, 2026
DataJan 2021–Oct 2026
Filing10-Q · Aug 6
Up next
filed Aug 6, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
−$204.69M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$334.54M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+36.5%
Year over year · more shares
Price change (1Y)
+178.3%
Trailing year
Short interest
15.0%
Latest settlement · 10.9 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Neutral
Sentiment
Neutral
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 15.1 · calm
Equity put/call 0.63
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+1%
above
Price vs 50-day avg
−19%
below
RSI (14)
36
neutral
MACD trend
Negative
52-week position
57%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−27%
trailing
6-month return
+6%
trailing
YTD return
+51%
this year
Relative strength
−5%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $19 › 200d $15 — 50d above 200d
Institutional flow
Distributing
3 of 184 funds reported for Sep 30 · net -79 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
14.96% of float · ▼ -7.2% MoM · 10.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
184 holders — near 3-yr high, broad support
Squeeze score
72
high risk · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
−255%
Y/Y
Free cash flow
$-175.8M
Quant / Vol
risk profile
Volatility
83%
annualized · 1-yr
Max drawdown
−37%
past year
ATR
7.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+1%
Bullish
Price vs 50-day avg
−19%
Bearish
RSI (14)
36
Neutral
MACD trend
Negative
Bearish
52-week position
57%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $19 › 200d $15 — 50d above 200d
Institutional flow
Distributing
3 of 184 funds reported for Sep 30 · net -79 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
14.96% of float · ▼ -7.2% MoM · 10.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
184 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $6
Now $16 · 57%
Range high $23
vs 200-day avg +1%
vs 50-day avg -19%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CGEM
this stock
Cullinan Therapeutics, Inc.
|
$965.19M | +51.0% | -100.0% | — | 15.0% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.16B | +11.5% | +46.2% | 29.5 | 1.9% |
|
MRNA
Moderna, Inc.
|
$78.44B | +566.3% | +4.3% | — | 8.2% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$76.40B | -3.9% | +20.8% | 18.4 | 2.5% |
|
CSLLY
Csl Ltd
|
$60.24B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CGEM | +1.8% | -26.7% | +6.0% | +1.8% | +51.0% |
| SPY | +1.9% | +1.9% | +10.8% | +1.9% | +14.0% |
| vs SPY | -0.1% | -28.6% | -4.7% | -0.1% | +37.0% |